Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (NASDAQ:TNYA) has selected TN-401 as a candidate gene therapy for treating genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) caused by PKP2 gene mutations, which affect over 70,000 patients in the U.S. Additionally, the company plans to submit IND applications for TN-201 and TN-301 in the latter half of 2022. Tenaya has appointed Jennifer Drimmer as General Counsel, bringing over 17 years of experience. The company aims to advance several therapeutic candidates towards clinical trials while enhancing its operational capabilities.
Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced significant changes to its Board of Directors, with the appointment of Dr. June Lee, who brings extensive experience in cardiovascular drug development. Dr. Lee was previously the Founder and CEO of Esker Therapeutics and held senior roles at MyoKardia and Genentech. She succeeds Dr. JJ Kang, who steps down after five years to focus on other ventures. The move reflects Tenaya's evolution towards becoming a clinical-stage company as it aims to advance therapies for heart disease.
Tenaya Therapeutics (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announces CEO Faraz Ali's participation in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2. A fireside chat webcast will be available starting November 22, 2021, at 10:00 a.m. ET. Founded by top cardiovascular scientists, Tenaya is dedicated to developing innovative treatments for both rare and common heart conditions through Gene Therapy, Cellular Regeneration, and Precision Medicine.
Tenaya Therapeutics, a biotechnology firm, reported significant advancements in its gene therapy programs and third quarter 2021 financial results. The company initiated a global natural history study for children with MYBPC3 mutations to enhance the TN-201 gene therapy development. Preclinical data demonstrated promising outcomes in murine models, highlighting durability in disease reversal. Tenaya's cash position stands strong at $280.5 million post-IPO, expected to sustain operations through late 2023. Despite a net loss of $18.3 million, the company continues its progress towards clinical-stage development.
Summary not available.
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in multiple key biotechnology conferences in October. Events include the Chardan 5th Annual Genetic Medicines Conference on October 4, featuring a panel discussion and a fireside chat. Ali will also speak at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on October 13, followed by a company presentation. Lastly, he will present at the Jefferies Gene Therapy/Editing Summit on October 28. Tenaya focuses on innovative therapies for heart disease.
Tenaya Therapeutics (TNYA) announced significant developments, including the granting of Orphan Drug Designation for its TN-201 gene therapy for genetic HCM by the FDA. The company successfully completed its IPO on August 3, 2021, raising $207 million. Leadership changes include Leone Patterson as Chief Financial Officer and Matt Pollman as SVP of Clinical Development. Financial results for Q2 2021 show a net loss of $15.2 million and R&D expenses of $10.9 million. Tenaya anticipates submitting IND applications for TN-201 and TYA-11631 in 2022.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announced that CEO Faraz Ali will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 2:45 p.m. ET. The company's mission is to develop curative therapies addressing heart disease's underlying causes through gene therapy, cellular regeneration, and precision medicine. Founded by top cardiovascular scientists, Tenaya aims to tackle both rare genetic disorders and more common heart conditions.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has successfully closed its upsized initial public offering, selling 13,800,000 shares at $15.00 each, totaling gross proceeds of $207.0 million. This offering included the full exercise of underwriters' options for 1,800,000 additional shares. Shares began trading on the Nasdaq Global Select Market on July 30, 2021. Morgan Stanley, Cowen, and Piper Sandler served as joint book-running managers, with Chardan leading the offering. The registration statements for this IPO were effective as of July 29, 2021.